

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CD3 FITC SK7 250 Tests CE

RRID:AB_2916364

Type: Antibody

Proper Citation

BD Biosciences Cat# 345764, RRID:AB_2916364

Antibody Information

URL: http://antibodyregistry.org/AB_2916364

Proper Citation: BD Biosciences Cat# 345764, RRID:AB_2916364

Target Antigen: CD3

Clonality: unknown

Comments: Applications: Flow Cytometry

Antibody Name: CD3 FITC SK7 250 Tests CE

Description: This unknown targets CD3

Clone ID: SK7

Antibody ID: AB_2916364

Vendor: BD Biosciences

Catalog Number: 345764

Record Creation Time: 20250820T031748+0000

Record Last Update: 20250820T155214+0000

Ratings and Alerts

No rating or validation information has been found for CD3 FITC SK7 250 Tests CE.

No alerts have been found for CD3 FITC SK7 250 Tests CE.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Aggarwal R, et al. (2025) Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3854.

Munoz-Couselo E, et al. (2025) Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer research communications, 5(2), 358.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell, 187(11), 2817.

Hansen AR, et al. (2024) Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(24), 5540.